Results for Calmark's initial biomarker, bilirubin, are within the expected range - project enters verification and validation phase to obtain CE mark
Calmark Sweden AB (publ) announces today that the development project for the Company's first biomarker, bilirubin, is now progressing to verification and validation. This phase, which is one of the final elements of the process, is estimated to last for approximately eight weeks. When it is completed, regulatory documentation will be compiled in order to achieve the CE Mark approval. This means that bilirubin will obtain its CE mark according to plan."Today's decision marks an important milestone for Calmark. We can now ascertain that we can satisfy our technical requirements on